The Jak2 Inhibitor, G6, Alleviates Jak2-V617F–Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow

The Jak2 Inhibitor, G6, Alleviates Jak2-V617F–Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow

We recently developed a Janus kinase 2 (Jak2) small-molecule inhibitor called G6 and found that it inhibits Jak2-V617F– mediated pathologic cell growth in vitro, ex vivo, and in vivo. However, its ability to inhibit Jak2-V617F–mediated myeloproliferative neoplasia, with particular emphasis in the b...

Full description

Bibliographic Details
Main Authors: Annet Kirabo, Sung O. Park, Anurima Majumder, Meghanath Gali, Mary K. Reinhard, Heather L. Wamsley, Zhizhuang Joe Zhao, Christopher R. Cogle, Kirpal S. Bisht, György M. Keserű, Peter P. Sayeski
Format: Article
Language:English
Published: Elsevier 2011-11-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558611800928

Internet

http://www.sciencedirect.com/science/article/pii/S1476558611800928

Similar Items